RESEARCH www.commprac.com ISSN 1462 2815 COMMUNITY PRACTITIONER 29 FEB Volume 21 Issue 02 ANALYTICAL METHOD, DEVELOPMENT AND VALIDATION FOR EVALUATING REPAGLINIDE EFFICACY IN TYPE II DIABETES MELLITUS MANAGEMENT: A PHARMACEUTICAL PERSPECTIVE Namrata Mishra 1 , M. Alagusundaram 2 , Dr. Anuja Sinha 3 , Aditya Vikram Jain 4 , Hasti. Kenia 5 , Suraj Mandal 6 and Dr. Mukta Sharma 7 * 1, 2 Department of Pharmaceutics, School of Pharmacy, ITM University, Turari, Gwalior, (M.P). 3 Associate Professor, Department of Anatomy, Manipal Tata Medical College, Jamshedpur. 4 Assistant Professor, College of Pharmacy, Teerthanker Mahaveer University, Delhi Road, Moradabad. 5 Assistant Professor, BLDEA'S Shri Sanganabasava Mahaswamiji College of Pharmacy and Research Centre, Vijayapura. 6 Assistant Professor, Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket, Ganganagar, Meeurt, U.P., India. 7 Professor, IIMT University, Meerut. (*Corresponding Author) DOI: 10.5281/zenodo.10642768 Abstract An anti-diabetic drug called Repaglinide is used to treat type II diabetes. Repaglinide, a lipophilic medication with a short (1 h) half-life and little solubility in water is classified as a class II biopharmaceutical chemical (BCS) chemical. Only around 55% of drugs with a high metabolism in the first pass are bioavailable orally. Repaglinide's half-life is one hour, and because of first-pass metabolism, it is 56% bioavailable in the body. Repaglinide requires frequent dosage because its total daily dose is 16 mg (e.g., 4 mg four times day depending on meal patterns). Repaglinide transdermal patches were created to maintain medication release, enhance drug bioavailability, and increase patient compliance Transdermal patch of Repaglinide was prepared to sustain the release and improve bioavailability of drug and patient compliance. Different formulations were prepared by varying the grades of HPMC and concentration of PVP K30 by solvent casting method. The prepared formulations were evaluated for various parameters like thickness, tensile strength, folding endurance, % elongation, % moisture content, % moisture uptake, % drug content, in vitro drug release, in vitro permeation, and drug excipient compatibility. Keywords: Repaglinide, Type II Diabetes, UV spectroscopy, FTIR. INTRODUCTION The largest and easiest to access organ of the body, the skin offers a potential route for medication delivery for systemic effects. Skin is divided into four layers, with the stratum corneum at the top serving as the most effective barrier against drug penetration and regulating the transdermal bioavailability of medications. To overcome the skin's natural barrier and deliver medication molecules with specific physicochemical properties to the systemic circulation, special transporters are therefore required. Transcutaneous administration of medications and vaccines is a practical substitute for oral and parenteral modes of administration. Hepatocytes can help prevent "first-pass" deactivation, lessen the risk of digestive discomfort, provide constant medication absorption over extended periods of time, and reduce drugging density, all of which improve adherence. The transcutaneous route has grown in popularity since ancient times because to its large external area and effects that facilitate drug administration. The most effective technique to arrange the drug administration is to avoid the skin because it is the most effective drug passage obstruction. It entails picking a method to deliver the dosage to the skin's surface. The